You are here: Industry Insights > Exparel

News List

Pacira Receives EC Approval for EXPAREL for Postsurgical Pain americanpharmaceuticalreview
November 26, 2020
Pacira BioSciences announced the European Commission has granted marketing authorization for EXPAREL as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of ...
Pacira Receives Positive CHMP Opinion for EXPAREL for Postsurgical Pain americanpharmaceuticalreview
September 27, 2020
Pacira BioSciences announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for EXPAREL for postsurgical analgesia.
CHMP backs seven new meds in September meeting pharmatimes
September 22, 2020
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended seven new medicines for approval in its latest meeting.
Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients americanpharmaceuticalreview
August 12, 2020
Pacira BioSciences announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include ...
Pacira Appoints Max Reinhardt as President contractpharma
June 20, 2019
Former Johnson & Johnson Executive brings extensive global experience leading multi-billion-dollar businesses to Pacira.
Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control pharmafocusasia
March 07, 2019
Pacira Pharmaceuticals, Inc. and MyoScience, Inc., a privately held medical technology company, today announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira.
Pacira to Acquire MyoScience americanpharmaceuticalreview
March 06, 2019
Pacira Pharmaceuticals and MyoScience, a privately held medical technology company, announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira.